Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma

References

• Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011 Aug;12(8):763–772. PubMed PMID: 21723781; PubMed Central PMCID: PMC3148430.
   PubMed Web of Science ®Google Scholar
• Bovolato P, Casadio C, Bille A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014 Mar;9(3):390–396. PubMed PMID: 24518090.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636–2644. PubMed PMID: 12860938.
   PubMed Web of Science ®Google Scholar
• Lam W-S, Lee YCG, Creaney J, et al. P2.06–026 A phase II trial of the oral FGF receptor inhibitor AZD4547 as 2nd or 3rd line therapy in malignant pleural mesothelioma - trial in progress: topic: mesothelioma and SCLC. J Thorac Oncol. 2017;12(1):S1087.
   Web of Science ®Google Scholar
• Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009 Sep;136(3):888–896. . PubMed PMID: 19736192
   PubMed Web of Science ®Google Scholar
• Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev. 2011 Nov;37(7):543–558. PubMed PMID: 21288646.
   PubMed Web of Science ®Google Scholar
• Janne PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15;62(18):5242–5247. PubMed PMID: 12234991
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001 Sep;37(Suppl 4):S9–15. PubMed PMID: 11597399
   PubMed Web of Science ®Google Scholar
• Pache JC, Janssen YM, Walsh ES, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol. 1998 Feb;152(2):333–340. PubMed PMID: 9466557; PubMed Central PMCID: PMCPMC1857975
   PubMed Web of Science ®Google Scholar
• Zanella CL, Timblin CR, Cummins A, et al. Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fos and apoptosis. Am J Physiol. 1999 Oct;277(4 Pt 1):L684–93. PubMed PMID: 10516208
   PubMed Web of Science ®Google Scholar
• Jaurand MC, Mechanisms of fiber-induced genotoxicity. Environ Health Perspect. 1997 Sep;105 Suppl 5:1073–1084. PubMed PMID: 9400703; PubMed Central PMCID: PMCPMC1470173.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Murakami H, Kawaguchi K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2009 Mar-Apr;2(2):181–188. PubMed PMID: 21475810.
   PubMed Web of Science ®Google Scholar
• Scapoli L, Ramos-Nino ME, Martinelli M, et al. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene. 2004 Jan 22;23(3):805–813. PubMed PMID: 14737115.
   PubMed Web of Science ®Google Scholar
• Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006 Feb;51(2):207–215. . PubMed PMID: 16384623.
   PubMed Web of Science ®Google Scholar
• Okuda K, Sasaki H, Kawano O, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2008 Oct;134(10):1105–1111. PubMed PMID: 18392851.
   PubMed Web of Science ®Google Scholar
• Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest oncology group study. J Clin Oncol. 2007 Jun 10;25(17):2406–2413. PubMed PMID: 17557954.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Lind MJ, Cawkwell L. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treat Rev. 2011 Nov;37(7):533–542. . PubMed PMID: 21183281
   PubMed Web of Science ®Google Scholar
• Rena O, Boldorini LR, Gaudino E, et al. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol. 2011 Nov 1;104(6):701–705. PubMed PMID: 21437912.
   PubMed Web of Science ®Google Scholar
• Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer. 2006 Dec;54(3):399–407. PubMed PMID: 17049671.
   PubMed Web of Science ®Google Scholar
• Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 1990 Jun;61(6):924–926. PubMed PMID: 2372497; PubMed Central PMCID: PMCPMC1971675
   PubMed Web of Science ®Google Scholar
• Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014 Nov 29;9:221. . PubMed PMID: 25432701; PubMed Central PMCID: PMCPMC4260254.
   PubMed Web of Science ®Google Scholar
• Choudhury KR, Yagle KJ, Swanson PE, et al. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem. 2010 Feb;58(2):95–107. PubMed PMID: 19687472; PubMed Central PMCID: PMCPMC2803710.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003 Oct 15;21(20):3798–3807. PubMed PMID: 12953099.
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012 Jan;13(1):33–42. PubMed PMID: 22056021.
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 02;373(9674):1525–1531. PubMed PMID: 19410716.
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Wynes MW, Singh S, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol. 2012 Feb;7(2):340–347. PubMed PMID: 22237262; PubMed Central PMCID: PMCPMC3358920.
   PubMed Web of Science ®Google Scholar
• Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol. 2006 Aug 15;1:19. . PubMed PMID: 16911776; PubMed Central PMCID: PMCPMC1560164.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005 May 04;97(9):643–655. PubMed PMID: 15870435.
   PubMed Web of Science ®Google Scholar
• Salvi S, Varesano S, Boccardo S, et al. EGFR status in Mesothelioma: possible implications for the efficacy of anti-EGFR and anti-MET therapies. J Thorac Oncol. 2016 Jun;11(6):e78–80. PubMed PMID: 27211582.
   PubMed Web of Science ®Google Scholar
• Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013 Feb;66(2):79–89. PubMed PMID: 23172555; PubMed Central PMCID: PMCPMC3582044.
   PubMed Web of Science ®Google Scholar
• Khoo C, Rogers TM, Fellowes A, et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res. 2015 Apr;4(2):126–141. PubMed PMID: 25870795; PubMed Central PMCID: PMCPMC4384221.
   PubMed Web of Science ®Google Scholar
• Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008 May;21(8):142. . PubMed PMID: 18495026; PubMed Central PMCID: PMCPMC2408599.
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar;39(3):347–351. PubMed PMID: 17293865.
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Kasai T, Takeda M, et al. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. J Clin Pathol. 2012 Jun;65(6):522–527. PubMed PMID: 22412050.
   PubMed Web of Science ®Google Scholar
• Schildgen V, Pabst O, Tillmann RL, et al. Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):118–125. PubMed PMID: 25679064.
   PubMedGoogle Scholar
• Teruhisa TFT, Kondo N, Okumura Y, et al., editor Mutation of epidermal growth factor receptor (EGFR) gene in malignant pleural mesothelioma. AACR Annual Meeting. Apr 12–16, 2008; San Diego, CA; 2008.
   Google Scholar
• Mezzapelle R, Miglio U, Rena O, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer. 2013 Apr 30;108(8):1743–1749. PubMed PMID: 23558893; PubMed Central PMCID: PMCPMC3668472.
   PubMed Web of Science ®Google Scholar
• Velcheti V, Kasai Y, Viswanathan AK, et al. Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol. 2009 Apr;4(4):559. PubMed PMID: 19333077.
   PubMed Web of Science ®Google Scholar
• Furukawa M, Toyooka S, Hayashi T, et al. DNA copy number gains in malignant pleural mesothelioma. Oncol Lett. 2015 Nov;10(5):3274–3278. PubMed PMID: 26722325; PubMed Central PMCID: PMCPMC4665758.
   PubMed Web of Science ®Google Scholar
• Onder SGG, Emri S, Firat P. EGFR expression and gene copy number in malignant pleural mesothelioma in Turkey. Int J Hematol Oncol. 2012;22:3.
   Google Scholar
• Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997 Dec;151(6):1523–1530. PubMed PMID: 9403702; PubMed Central PMCID: PMCPMC1858348
   PubMed Web of Science ®Google Scholar
• Govindan R, Kratzke RA, Herndon JE 2nd. et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B. Clin Cancer Res. 2005 Mar 15;11(6):2300–2304. . PubMed PMID: 15788680.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123–132. PubMed PMID: 16014882.
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809–1818. PubMed PMID: 19027483.
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528–538. PubMed PMID: 22452896.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2017 Aug 25:JCO2017747576. DOI:10.1200/JCO.2017.74.7576. PubMed PMID: 28841389.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733–2743. PubMed PMID: 17192538.
   PubMed Web of Science ®Google Scholar
• Felip E, Remon J, Steuer CE, et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29(suppl_1):i20–i27.
   PubMed Web of Science ®Google Scholar
• Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001 Sep 1;61(17):6500–6510. PubMed PMID: 11522647
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311–1318. PubMed PMID: 9815926
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O‘Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 Nov 15;357(20):2040–2048. PubMed PMID: 18003960.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 May 1;25(13):1658–1664. PubMed PMID: 17470858.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009 Jan-Feb;1(1):41–48. PubMed PMID: 20046573; PubMed Central PMCID: PMCPMC2715181
   PubMed Web of Science ®Google Scholar
• Reardon DA, Lassman AB, van Den Bent M, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. 2017 Jul 1;19(7):965–975. PubMed PMID: 28039367; PubMed Central PMCID: PMCPMC5570193.
   PubMed Web of Science ®Google Scholar
• Barbieri F, Wurth R, Favoni RE, et al. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets. Biochem Pharmacol. 2011 Nov 15;82(10):1467–1477. PubMed PMID: 21787763.
   PubMed Web of Science ®Google Scholar
• Liu Z, Klominek J. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. Neoplasia. 2004 Nov-Dec;6(6):705–712. . PubMed PMID: 15720796; PubMed Central PMCID: PMCPMC1531674
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129–2139. PubMed PMID: 15118073.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005 Apr 10;23(11):2513–2520. PubMed PMID: 15738541.
   PubMed Web of Science ®Google Scholar
• Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res off J Am Assoc Cancer Res. 2005 Aug 15;11(16):5878–5885. PubMed PMID: 16115929.
   PubMed Web of Science ®Google Scholar
• Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer. 2007 Mar 26;96(6):857–863. . PubMed PMID: 17325698; PubMed Central PMCID: PMCPMC2360106.
   PubMed Web of Science ®Google Scholar
• Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010 Jun;133(6):922–934. PubMed PMID: 20472851; PubMed Central PMCID: PMCPMC3156055.
   PubMed Web of Science ®Google Scholar
• Agatsuma N, Yasuda Y, Ozasa H. Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with afatinib. J Thorac Oncol. 2017 Sep;12(9):e141–e143. . PubMed PMID: 28838714
   PubMedGoogle Scholar
• Foster JM, Gatalica Z, Lilleberg S, et al. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol. 2009 Jan;16(1):152–158. PubMed PMID: 18998063.
   PubMed Web of Science ®Google Scholar
• Foster JM, Radhakrishna U, Govindarajan V, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol. 2010 Oct;13(8):88. . PubMed PMID: 20942962; PubMed Central PMCID: PMCPMC2970593.
   PubMed Web of Science ®Google Scholar
• Erlotinib hydrochloride in treating patients with malignant peritoneal mesothelioma (NCT01592383) 2017 [cited 2017 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT01592383
   Google Scholar
• Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15;113(4):808–814. PubMed PMID: 18543326.
   PubMed Web of Science ®Google Scholar
• van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017 Oct;18(10):1386–1396. . PubMed PMID: 28870611.
   PubMed Web of Science ®Google Scholar
• University Hospital G. Study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma (MesoMab NCT00996567). [cited 2018 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT00996567
   Google Scholar
• Brevet M, Shimizu S, Bott MJ, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol. 2011 May;6(5):864–874. PubMed PMID: 21774103.
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res off J Am Assoc Cancer Res. 2007 Mar 1;13(5):1552–1561. PubMed PMID: 17332301.
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, et al. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Int J Oncol. 2012 Nov;41(5):1610–1618. PubMed PMID: 22922885; PubMed Central PMCID: PMCPMC3583649.
   PubMed Web of Science ®Google Scholar
• Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991 Jan 16;83(2):97–104. PubMed PMID: 1988695
   PubMedGoogle Scholar
• Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001 Jun;144(6):1169–1176. PubMed PMID: 11422037
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005 Jul 1;11(13):4810–4817. PubMed PMID: 16000578.
   PubMed Web of Science ®Google Scholar
• Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013 Jul-Aug;63(4):249–279. . PubMed PMID: 23716430
   PubMed Web of Science ®Google Scholar
• Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009 Jul 15;69(14):5851–5859. PubMed PMID: 19584289.
   PubMed Web of Science ®Google Scholar
• Saé Muñiz-Hernández VI-S, Mendoza-Desión JA, González-Torres C, et al., editor Abstract 25: effect of nimotuzumab on malignant pleural mesothelioma cell lines. AACR Annual Meeting 2017 April 1–5, 2017; Washington, DC.
   Google Scholar
• Foundation ADR. mesomiR 1: a phase I study of targomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC (NCT02369198) 2017 [cited 2019 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02369198
   Google Scholar
• Wright C, Williams M, Kirschner MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–3135.
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016 Feb;6(2):133–146. . PubMed PMID: 26503962; PubMed Central PMCID: PMCPMC4744527
   PubMed Web of Science ®Google Scholar
• Hassan R, Thomas A, Alewine C, et al. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol. 2016 Dec;34(34):4171–4179. PubMed PMID: 27863199; PubMed Central PMCID: PMCPMC5477819.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Hassan R, Moore KN, et al. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). J clin oncol. 2016;34(15_suppl):2509.
   PubMed Web of Science ®Google Scholar
• Hassan R, Jennens R, Meerbeeck JPV, et al. A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). J clin oncol. 2016;34(15_suppl):TPS8576–TPS8576.
   Web of Science ®Google Scholar
• Kindler HL, Novello S, Fennell D, et al. OA 02.01 randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma. J Thorac Oncol. 2017;12(11):S1746.
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res off J Am Assoc Cancer Res. 2014 Dec 1;20(23):5927–5936. PubMed PMID: 25231400; PubMed Central PMCID: PMCPMC4252585.
   PubMed Web of Science ®Google Scholar
• Gan HK, Burgess AW, Clayton AH, et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012 Jun 15;72(12):2924–2930. PubMed PMID: 22659454..
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007 Mar 06;104(10):4071–4076. PubMed PMID: 17360479; PubMed Central PMCID: PMCPMC1805701.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Bovee TD, Meyer DW, et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem. 2008 Oct;19(10):1960–1963. PubMed PMID: 18803412.
   PubMed Web of Science ®Google Scholar
• Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661–669. PubMed PMID: 26846818.
   PubMed Web of Science ®Google Scholar
• Bent MJVD, Gan HK, Lassman AB, et al. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM). J clin oncol. 2016;34(15_suppl):2542.
   Web of Science ®Google Scholar
• Bent MJVD, French P, Eoli M, et al. Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406) [Internet]. Chicago. J Clin Oncol. 2018;36(15_suppl):2023–2023. Available from: http://abstracts.asco.org/214/AbstView_214_211873.html
   Web of Science ®Google Scholar
• Macsai-Kaplan ANM. Corneal Toxicity of ABT-414, an investigational drug for Glioblastoma. Invest Ophthalmol Visual Sci. 2015;56(7):1188.
   Web of Science ®Google Scholar
• AbbVie. A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands (NCT03234712). 2017.
   Google Scholar
• Chia PL, Cao D, Rigopoulos A, et al. Abstract 743: ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma in vivo. Cancer Res. 2018;78(13Supplement):743.
   Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. PubMed PMID: 24553386; PubMed Central PMCID: PMCPMC4684949.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014 Feb;2(2):112–120. PubMed PMID: 24579088; PubMed Central PMCID: PMCPMC3932715.
   PubMed Web of Science ®Google Scholar
• Mayor M, Zeltsman M, McGee E, et al. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial. Immunotherapy. 2016 May;8(5):491–494. PubMed PMID: 27140404.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 5;6(261):261ra151. PubMed PMID: 25378643; PubMed Central PMCID: PMCPMC4373413.
   PubMed Web of Science ®Google Scholar
• Center MSKC. Malignant pleural disease treated with autologous T cells genetically engineered to target the cancer-cell surface antigen mesothelin 2018 [cited 2018 apr 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02414269
   Google Scholar
• Kiesgen S, Chicaybam L, Chintala NK, et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J Thorac Oncol. 2018 Jan;13(1):16–26. PubMed PMID: 29107016; PubMed Central PMCID: PMCPMC5738277.
   PubMed Web of Science ®Google Scholar
• Li H, Huang Y, Jiang DQ, et al. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis. 2018 Feb 7;9(2):177. PubMed PMID: 29415996; PubMed Central PMCID: PMCPMC5833445.
   PubMed Web of Science ®Google Scholar
• Hospital SCs. EGFR806 CAR T cell immunotherapy for recurrent/refractory solid tumors in children and young adults (NCT03618381) 2018 [cited 2018 oct 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03618381
   Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017 May;18(5):623–630. PubMed PMID: 28291584.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial. J clin oncol. 2017;35(18_suppl):LBA8507–LBA8507.
   Web of Science ®Google Scholar
• Ahn MJ, Sun JM, Lee SH, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017 Apr;16(4):465–469. PubMed PMID: 28271729.
   PubMed Web of Science ®Google Scholar
• Varesano S, Salvi S, Boccardo S, et al. MET gene status in malignant mesothelioma using fluorescent in situ hybridization. J Thorac Oncol. 2016 Feb;11(2):e28–30. PubMed PMID: 26811229.
   PubMed Web of Science ®Google Scholar